Researchers conducted a clinical trial to see if a drug called hydroxychloroquine (HCQ) could prevent rheumatoid arthritis (RA) from developing. They studied 144 people who were at high risk for RA because they had elevated levels of a specific antibody in their blood. Half took HCQ for a year, and half took a placebo pill. The main goal was to see how many people developed full clinical RA over a total of 36 months, including follow-up time after stopping the pills.
After three years, the results showed no meaningful difference between the two groups. About 30% of people taking HCQ developed RA, compared to about 33% of those taking the placebo. The difference was so small that it could easily be due to chance. The study also found no difference in other measures, like participant-reported joint symptoms.
This was a phase 2 trial, which means it is an early-stage study designed to get initial answers. The number of participants was moderate, and the statistical results included a wide range of possibilities, from a potential small benefit to a potential small harm. The findings suggest that a 12-month course of HCQ is not an effective strategy for preventing RA in this specific high-risk group. More research is needed to find other possible prevention methods.
